Sasikumar PG - Search Results

1

Small-molecule antagonists of the immune checkpoint pathways: concept to clinic.

Sasikumar PG, Ramachandra M. Sasikumar PG, et al. Future Med Chem. 2017 Aug;9(12):1305-1308. doi: 10.4155/fmc-2017-0107. Epub 2017 Aug 3. Future Med Chem. 2017. PMID: 28771036 No abstract available.

2

Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways.

Sasikumar PG, Ramachandra M. Sasikumar PG, et al. BioDrugs. 2018 Oct;32(5):481-497. doi: 10.1007/s40259-018-0303-4. BioDrugs. 2018. PMID: 30168070 Review.

3

PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy.

Sasikumar PG, Sudarshan NS, Adurthi S, Ramachandra RK, Samiulla DS, Lakshminarasimhan A, Ramanathan A, Chandrasekhar T, Dhudashiya AA, Talapati SR, Gowda N, Palakolanu S, Mani J, Srinivasrao B, Joseph D, Kumar N, Nair R, Atreya HS, Gowda N, Ramachandra M. Sasikumar PG, et al. Commun Biol. 2021 Jun 8;4(1):699. doi: 10.1038/s42003-021-02191-1. Commun Biol. 2021. PMID: 34103659 Free PMC article.

4

Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development.

Sasikumar PG, Ramachandra M. Sasikumar PG, et al. Front Immunol. 2022 May 2;13:752065. doi: 10.3389/fimmu.2022.752065. eCollection 2022. Front Immunol. 2022. PMID: 35585982 Free PMC article. Review.

5

Anti-PD-L1 peptide improves survival in sepsis.

Shindo Y, McDonough JS, Chang KC, Ramachandra M, Sasikumar PG, Hotchkiss RS. Shindo Y, et al. Among authors: sasikumar pg. J Surg Res. 2017 Feb;208:33-39. doi: 10.1016/j.jss.2016.08.099. Epub 2016 Sep 8. J Surg Res. 2017. PMID: 27993215 Free PMC article.

6

A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy.

Sasikumar PG, Ramachandra RK, Adurthi S, Dhudashiya AA, Vadlamani S, Vemula K, Vunnum S, Satyam LK, Samiulla DS, Subbarao K, Nair R, Shrimali R, Gowda N, Ramachandra M. Sasikumar PG, et al. Mol Cancer Ther. 2019 Jun;18(6):1081-1091. doi: 10.1158/1535-7163.MCT-18-0737. Epub 2019 Apr 23. Mol Cancer Ther. 2019. PMID: 31015307

7

Peptide hormone isoforms: N-terminally branched PYY3-36 isoforms give improved lipid and fat-cell metabolism in diet-induced obese mice.

Pedersen SL, Sasikumar PG, Chelur S, Holst B, Artmann A, Jensen KJ, Vrang N. Pedersen SL, et al. Among authors: sasikumar pg. J Pept Sci. 2010 Nov;16(11):664-73. doi: 10.1002/psc.1281. J Pept Sci. 2010. PMID: 20853314

8

Peptide architecture: adding an alpha-helix to the PYY lysine side chain provides nanomolar binding and body-weight-lowering effects.

Pedersen SL, Sasikumar PG, Vrang N, Jensen KJ. Pedersen SL, et al. Among authors: sasikumar pg. ChemMedChem. 2010 Apr 6;5(4):545-51. doi: 10.1002/cmdc.200900521. ChemMedChem. 2010. PMID: 20183851

9

Synthesis of retro acyl carrier protein (74-65) fragment on a new glycerol based polystyrene support.

Sasikumar PG, Kumar KS, Pillai VN. Sasikumar PG, et al. Protein Pept Lett. 2003 Oct;10(5):427-33. doi: 10.2174/0929866033478753. Protein Pept Lett. 2003. PMID: 14561130

10

Tri(propylene glycol) glycerolate diacrylate cross-linked polystyrene: a new resin support for solid-phase peptide synthesis.

Sasikumar PG, Kumar KS, Rajasekharan Pillai VN. Sasikumar PG, et al. J Pept Res. 2003 Jul;62(1):1-10. doi: 10.1034/j.1399-3011.2003.00057.x. J Pept Res. 2003. PMID: 12787445

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11 results

Search Page

Filters